A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Multiple Dose Regimens of Once-Weekly Switching to Once-Monthly MET097 in Participants With Obesity or Overweight (VESPER-3)
Latest Information Update: 11 Jun 2025
At a glance
- Drugs MET 097 (Primary)
- Indications Metabolic disorders; Obesity
- Focus Therapeutic Use
- Acronyms VESPER-3
- Sponsors Metsera
Most Recent Events
- 04 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 15 May 2025 Status changed from planning to recruiting.
- 02 Apr 2025 New trial record